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Signal peptide peptidase-like 3 (SPPL3) is a Golgi-resident
intramembrane-cleaving protease that is highly con-
served among multicellular eukaryotes pointing to pivotal
physiological functions in the Golgi network which are
only beginning to emerge. Recently, SPPL3 was shown to
control protein N-glycosylation, when the key branching
enzyme N-acetylglucosaminyltransferase V (GnT-V) and
other medial/trans Golgi glycosyltransferases were iden-
tified as first physiological SPPL3 substrates. SPPL3-me-
diated endoproteolysis releases the catalytic ectodo-
mains of these enzymes from their type II membrane
anchors. Protein glycosylation is a multistep process in-
volving numerous type II membrane-bound enzymes, but
it remains unclear whether only few of them are SPPL3
substrates or whether SPPL3 cleaves many of them and
thereby controls protein glycosylation at multiple levels.
Therefore, to systematically identify SPPL3 substrates
we used Sppl3-deficient and SPPL3-overexpression cell
culture models and analyzed them for changes in se-
creted membrane protein ectodomains using the pro-
teomics “secretome protein enrichment with click sugars
(SPECS)” method. SPECS analysis identified numerous
additional new SPPL3 candidate glycoprotein substrates,
several of which were biochemically validated as SPPL3
substrates. All novel SPPL3 substrates adopt a type II
topology. The majority localizes to the Golgi network and
is implicated in Golgi functions. Importantly, most of the
novel SPPL3 substrates catalyze the modification of N-
linked glycans. Others contribute to O-glycan and in par-
ticular glycosaminoglycan biosynthesis, suggesting that
SPPL3 function is not restricted to N-glycosylation, but
also functions in other forms of protein glycosylation.
Hence, SPPL3 emerges as a crucial player of Golgi func-
tion and the newly identified SPPL3 substrates will be
instrumental to investigate the molecular mechanisms
underlying the physiological function of SPPL3 in the
Golgi network and in vivo. Data are available via Pro-
teomeXchange with identifier PXD001672. Molecular
& Cellular Proteomics 14: 10.1074/mcp.M115.048298,
1584–1598, 2015.
Signal peptide peptidase (SPP)1 and SPP-like (SPPL) pro-
teases belong to the GxGD family of intramembrane-cleaving
aspartyl proteases, which also comprises the presenilins, the
From the aDZNE – German Center for Neurodegenerative Diseases,
Munich, Germany; bInstitute for Advanced Study, Technische Univer-
sität München, Garching, Germany; cInstitute for Metabolic Biochem-
istry, Ludwig-Maximilians University Munich, Munich, Germany;
dBiochemical Institute, Christian-Albrechts University Kiel, Ol-
shausenstrasse 40, D-24118 Kiel, Germany; eInstitute of Toxicology
and Genetics, KIT, Campus North, Hermann-von-Helmholtz-Platz 1,
D-76344 Eggenstein-Leopoldshafen, Germany Munich Cluster for
Systems Neurology (SyNergy), Munich, Germany; fMunich Cluster for
Systems Neurology (SyNergy), Munich, Germany; gNeuroproteomics,
Klinikum rechts der Isar, Technische Universität München, Munich,
Germany
Received February 3, 2015, and in revised form, March 30, 2015
Published, MCP Papers in Press March 31, 2015, DOI 10.1074/
mcp.M115.048298
Author contributions: P.K., M.V., S.F.L., and R.F. designed re-
search; P.K., M.V., and M.H. performed research; B.S., U.S., and S.B.
contributed new reagents or analytic tools; P.K., M.V., S.F.L., and R.F.
analyzed data; P.K., M.V., S.F.L., and R.F. wrote the paper. C.H.,
S.F.L. and R.F. supervised research.
1 The abbreviations used are: SPP, signal peptide peptidase;
ASPH, aspartyl/asparaginyl -hydroxylase; 3GalT6, 1,3 galacto-
syltransferase 6; 3GnT1, 1,3 N-acetylglucosaminyltransferase 1;
4GalT1, 1,4 galactosyltransferase 1; BACE1, -site amyloid
precursor protein converting enzyme 1; CANT1, calcium-activated
nucleotidase 1; EXTL3, exostosin-like 3; GalNAcT-10, polypeptide
N-acetylgalactosaminyltransferase 10; GnT-V, 1,6 N-acetylgluco-
saminyltransferase V; HS6ST1, heparan sulfate 6-O-sulfotransferase
1; HS6ST2, heparan sulfate 6-O-sulfotransferase 2; ManAz, tet-
raacetyl-N-azidoacetyl mannosamine; MEF, murine embryonic fibro-
blasts; NDST1, bifunctional heparin sulfate N-deacetylase/N-sulfo-
transferase 1; NFAT, nuclear factor of activated T cells; OGFOD3,
2-oxoglutarate and iron-dependent oxygenase domain-containing
protein 3; QARIP, quantitative analysis of regulated intramembrane
proteolysis; Sgk196, protein kinase-like protein Sgk196; SPECS, se-
cretome protein enrichment with click sugars; SPPL, signal peptide
peptidase-like; ST6Gal1, -galactoside 2,6 sialyltransferase 1; TMD,
transmembrane domain; TOR1AIP1, torsin 1A-interacting protein 1;
XylT2, xylosyltransferase 2.
Research
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.
This paper is available on line at http://www.mcponline.org
1584 Molecular & Cellular Proteomics 14.6











catalytically active subunits of -secretase, implicated in Alz-
heimer’s disease etiology (1). These proteases are multipass
membrane proteins and their active site is buried within the
membrane’s hydrophobic interior. Similar to other intramem-
brane-cleaving proteases, SPP/SPPLs endoproteolyse mem-
brane protein substrates within or adjacent to their mem-
brane-spanning regions. In contrast to the well-documented
selectivity of presenilins for type I membrane protein sub-
strates, SPP/SPPLs appear to favor substrates adopting a
type II topology in the membrane (1). In mammals, genes
encoding five SPP/SPPL proteases (SPP, SPPL2a, SPPL2b,
SPPL2c, and SPPL3) have been identified (2–4) and sub-
strates have been described for all but SPPL2c (reviewed in
(1)). Although SPP, SPPL2b, and -secretase only accept
substrates with a rather short ectodomain (5–7) and thus
usually require a preceding release of the substrates’ ectodo-
main (shedding) SPPL3 was recently shown to directly endo-
proteolyse full-length membrane protein substrates close to
their predicted transmembrane segments without prior ecto-
domain shedding (8, 9). Thus, SPPL3 unexpectedly acts as a
type II membrane protein-selective sheddase catalyzing the
release and secretion of the substrates’ ectodomain.
SPPL3 orthologs are found in most multicellular eukaryotes
and the degree of conservation is extraordinarily high pointing
to a pivotal physiological function (1). Following up altered
cellular N-glycosylation patterns associated with elevated or
reduced SPPL3 expression in vitro and in vivo, Golgi-resident
glycosyltransferases including the N-glycan branching en-
zyme N-acetylglucosaminyltransferase V (GnT-V) were re-
cently uncovered as the first physiological type II membrane
protein substrates of SPPL3 (9). Meanwhile, SPPL3 has ad-
ditionally been shown to modulate cytosolic Ca2 release and
NFAT (nuclear factor of activated T cells) signaling following
T-cell receptor engagement apparently in a nonproteolytic
fashion (10).
The cleavage mechanism of SPPL3 in contrast to that of
-secretase, SPP and SPPL2b has not been investigated in
more detail. -secretase, SPP and SPPL2b catalyze multiple
cleavages within the center of the substrates’ transmembrane
domain to release the corresponding cleavage products into
the cytosol or the extracellular space, respectively (reviewed
in (1, 11)). In contrast to SPP and SPPL2b, SPPL3 seems to
cleave its substrates within the C-terminal region of the sub-
strates’ transmembrane or possibly even within the jux-
tamembrane domain. This assumption, however, is based
solely on the cleavage site of SPPL3 within GnT-V, which has
been recently mapped (9). In order to fully understand how the
individual members of the GxGD intramembrane protease
family recognize and cleave their substrates it is crucial to
map further cleavage sites.
Protease substrates can be identified with proteomic tech-
niques that have already proven themselves as powerful tools
for the identification of novel protease substrates and the
in-depth characterization of protease degradomes (12). How-
ever, reliable detection of quantitative changes of rather small
or very hydrophobic proteolytic cleavage products as a result
of the successive proteolytic processing of membrane protein
substrates by intramembrane proteases is challenging with
proteomic approaches. Recent studies that aimed at identi-
fying novel substrates of -secretase (13), SPP (14), and
SPPL2a/SPPL2b (15) in cell culture observed a measurable
accumulation of substrates in cellular membranes following
pharmacological inhibition of the respective protease(s) or
their genomic ablation. However, for SPP and SPPL2a/
SPPL2b, these approaches only uncovered very few new
candidate substrates (14, 15).
Here we identified novel SPPL3 substrates in a cell culture
model over-expressing SPPL3 and in Sppl3-deficient cells. To
circumvent previous difficulties with substrate identification
for intramembrane proteases, we made use of the fact that
SPPL3 cleavage results in the release of the substrates’ ect-
odomain into the conditioned medium (also referred to as
secretome) (9). There, proteomic identification and quantifica-
tion of a membrane protein’s ectodomain allows the protein to
be scored as a SPPL3 substrate candidate, if the ectodomain
levels are increased upon SPPL3 overxpression or reduced
when SPPL3 is not expressed. To this aim we used the
previously developed “secretome protein enrichment with
click sugars” (SPECS) technology, which allows proteomic
analysis of cellular secretomes at unprecedented depth en-
riching glycoproteins but renders nonglycosylated proteins
invisible to detection. SPECS was previously used success-
fully to identify novel substrates of another membrane-bound
protease, the -site APP cleaving enzyme 1 (BACE1) (16).
We now employed this technology to define the spec-
trum of SPPL3 substrates in human and murine cell culture
models. Besides the previously identified SPPL3 substrates
(9), SPECS analyses of the same cell culture models revealed
numerous additional candidate glycoprotein SPPL3 sub-
strates. Interestingly, the majority of these novel substrates
are type II-membrane Golgi-resident factors implicated in
multiple cellular glycosylation pathways. This confirms
SPPL3’s crucial role in cellular N-glycosylation but also un-
derscores a more general role of SPPL3 in Golgi homoeosta-
sis and regulation of cellular glycosylation pathways. Hence,
this study complements the substrate spectrum of SPPL3,
confirms its role as a type II membrane protein-selective
sheddase and underscores the importance of SPPL3 in Golgi
biology.
MATERIALS AND METHODS
Cell Lines, Antibodies, and Reagents—HEK293 T-Rex™ cells sta-
bly expressing ectopic, HA epitope-tagged SPPL3 under control of a
doxycycline-inducible CMV promoter are described elsewhere (17)
and were kept under standard conditions. Immortalized Sppl3/ and
Sppl3/ mouse embryonic fibroblast (MEF) lines had been originally
obtained from litter-mate embryos and were described recently (9).
siRNA pools targeting SPPL3 (#M-006042-02), EXTL3 (#M-012578-
00), XYLT2 (#M-013040-01), B3GALT6 (#M-021340-01), HS6ST1
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(#M-011944-01), HS6ST2 (#M-015558-01), and SGK196 (#M-
005321-00) as well as a nontargeting control siRNA pool were pur-
chased from Thermo Fisher Scientific (Waltham, MA). Antibodies
used for substrate validation by immunoblotting were purchased from
the following commercial sources: anti-ASPH (pAb, H-300, Santa
Cruz Biotechnologies, Dallas, TX), anti-4GalT1 (pAb, AF3609, R&D
Systems, Minneapolis, MN), anti-3GalT6 (pAb, ab103375, Abcam,
Cambridge, UK), anti-Calnexin (pAb, Enzo Life Sciences, Farm-
ingdale, NY), anti-Cant1 (mAb, 861206, R&D Systems), anti-EXTL3
(mAb, clone G-5, Santa Cruz Biotechnologies), anti-GalNAcT10 (pAb,
AF7575, R&D Systems), anti-GnT-V (mAb, clone 706824, R&D Sys-
tems), anti-HS6ST1 (pAb, AF5057, R&D Systems), anti-HS6ST2 (pAb,
HPA034625, Sigma, St. Louis, MO), anti-Integrin 5 (pAb, 4705, Cell
Signaling Technology, Cambridge, UK), anti-OGFOD3 (mAb, clone
F-19, Santa Cruz Biotechnologies), anti-Sgk196 (mAb, clone S-23,
Santa Cruz Biotechnologies), anti-TOR1AIP1 (pAb, 60–1001, EMD
Millipore, Billerica, MA), anti-TOR1AIP1 (pAb, NBP1–19122, Novus
Biologicals, Littleton, CO), and anti-XylT2 (mAb, clone G-1, Santa
Cruz Biotechnologies). The anti-Sppl3 mAb (clone 7F9) was de-
scribed earlier (8). ManNAz was synthesized as previously described
(16, 18). DBCO-PEG12-Biotin was obtained from Click Chemistry
Tools (Scottsdale, AZ).
SPECS Workflow—Secretome enrichment and subsequent pro-
teomic analyses were essentially performed as detailed earlier (16). In
brief, 40 million cells were plated and incubated for 48 h in 20 ml
DMEM supplemented with 10% (v/v) FCS and 200 nM tetraacetyl-N-
azidoacetyl mannosamine (ManNAz). Cells ectopically expressing
SPPL3 were pre-incubated with media supplemented with 1 g/ml
doxycycline and labeling was likewise performed in the presence of
doxycycline. Conditioned media were collected and filtered through
0.45 mm PVDF filter (Millex) into a VivaSpin 20 ultrafiltration unit
(cutoff, 30 kDa) at 4 °C. VivaSpin 20 columns were centrifuged at
4600 r.p.m. at 4 °C to remove nonmetabolized ManNAz. The retentate
was filled with 20 ml H2O. This procedure was repeated three times.
In the last step, the H2O refill step was omitted. Instead, 100 nM of
DBCO-PEG12-biotin (Click-chemistry tools) diluted in 1 ml ddH2O
was added to biotinylate metabolically azide-labeled glycoproteins.
Columns were incubated overnight at 4 °C. For removal of nonre-
acted DBCO-PEG12-Biotin, VivaSpin20 columns were subject to
three times of centrifugation with subsequent PBS buffer refill. After
the last centrifugation step, the retentate was diluted in 5 ml PBS with
2% SDS (v/v) and 2 mM Tris(2-carboxyethyl)phosphine (TCEP). For
purification of biotinylated proteins, the sample was loaded on a
10-ml polyprep column with a streptavidin bed of 300 l streptavidin
slurry. After binding of proteins, streptavidin beads were washed 3
times with 10 ml PBS supplemented with 1% SDS. To elute the
biotinylated and azide-labeled glycoproteins, streptavidin beads were
boiled with urea sample buffer containing 3 mM biotin to compete for
the binding of biotinylated proteins.
SDS-PAGE Separation, Trypsinization—Proteins were separated
on a 10% Tris/glycine SDS gel. Afterward, qualitatively equal gel
slices were cut out from the gel with the exception of the remaining
albumin band at around 60 kDa. Proteins in the gel slices were subject
to trypsinization according to standard protocols (19).
Mass Spectrometric Analysis—Mass spectrometry experiments
were performed on an Easy nLCnanoflow HPLC system II (Proxeon)
connected to an LTQ-Velos Orbitrap Pro (Thermo Fisher Scientific).
Peptides were separated by reverse phase chromatography using
in-house made 30 cm columns (New Objective, FS360-75-8-N-S-
C30) packed with C18-AQ 2.4 mm resin (Dr Maisch GmbH, Part No.
r124.aq). A 90-min gradient (5–40%) at a flow rate of 200 nl/min was
used. The measurement method consisted of an initial FTMS scan
recorded in profile mode with 30 000 m/z resolution, a mass range
from 300 to 2000 m/z and a target value of 1,000,000. Subsequently,
collision-induced dissociation (CID) fragmentation was performed for
the 15 most intense ions with an isolation width of 2 Da in the ion trap.
A target value of 10,000, enabled charge state screening, a monoiso-
topic precursor selection, 35% normalized collision energy, an acti-
vation time of 10 ms, wide band activation and a dynamic exclusion
list with 30 s exclusion time were applied.
Analysis of Mass Spectrometry Data—For data analysis five bio-
logical replicates of the HEK293T secretome were analyzed with the
freely available MaxQuant suite (version 1.4.1.2) and five biological
replicates with two technical replicates of the MEF secretome were
analyzed with the freely available MaxQuant suite (version 1.5.0.124)
(20). Protein identification was performed using the integrated An-
dromeda search algorithm (21). Mass recalibration was done by a first
search in a reduced murine protein database. First search, mass
recalibration and Mmain search was of tryptic peptides were per-
formed using a human Uniprot database downloaded 08/21/2012
(86749 entries) for the HEK293T secretome and a murine Uniprot
database downloaded on 05/16/2014 (version 3.68) (51389 entries)
for the MEF secretome allowing for N-terminal acetylation and
oxidation of methionine as variable modifications and carbamidom-
ethylation of cysteine as fixed modifications. Two missed cleavages
were allowed. Peptide as well as protein false discovery rate was set
to 1%. Mass accuracy was set to 20 ppm for the first search and 5
ppm for the main search. Label-free quantification (LFQ) was per-
formed between the respective control and Sppl3 knockout or SPPL3
overexpression control and SPPL3 overexpression or knockout con-
ditions on the basis of unique and razore peptides. Missing LFQLFQ
values were imputed in Perseus 1.5.16 following a standard distribu-
tion. p values were calculated with a heteroscedastic, two-sided
student’s t test for all proteins based on the log2 transformed
absolute LFQ values in case of the HEK293 secretome and on log2
transformed relative intensity ratio values for the MEF secretome
where two technical replicates allowed calculation of the variance
within one biological replicate. Proteins with a p value of p  0.05
were considered as hits. MaxQuant output files (protein groups
and peptides) (supplemental Table S2–S3 and S5–S6) and calculated
values (supplemental Table S1 and S4) for both data sets are at-
tached as supplementary files. The mass spectrometry proteomics
raw data including MaxQuant outputfiles have been deposited
to at the ProteomeXchange Consortium (http://proteomecentral.
proteomexchange.org) via the PRIDE partner repository with the data
set identifier PXD001672. GO term analysis was performed on the
SPPL3 overexpression data set considering elevated type II mem-
brane proteins as hits and the remaining secretome as background
using GOrilla (http://cbl-gorilla.cs.technion.ac.il/) (22).
Substrate Validation by Immunoblotting—HEK293 cells were trans-
fected with siRNA pools at a final concentration of 20 nM using
Lipofectamine® RNAiMax (Life Technologies, Carlsbad, CA) accord-
ing to the manufacturer’s instructions. Ectopic expression of catalyt-
ically active SPPL3 was induced by supplementing cell culture media
with 1 g/ml doxycycline. 48 h after transfection or 48 h after doxy-
cycline mediated induction of SPPL3 overexpression cells were
washed twice with prewarmed Opti-MEM™ (Life Technologies) and
then cultivated in Opti-MEM™ for additional 48 h. Conditioned su-
pernatants of MEFs were collected for 8 h. All supernatants were
cleared from detached cells by centrifugation and secreted proteins
were isolated by TCA precipitation (9). Supernatant samples were
normalized to lysate protein content prior to loading. Cell lysis, SDS-
PAGE and immunoblotting were conducted as described earlier (9).
RESULTS
Identification of Novel SPPL3 Substrates in Cells Ectopically
Expressing SPPL3—Because SPPL3 was previously shown
to endoproteolyse individual full-length type II membrane pro-
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teins triggering their secretion (8, 9), we applied a mass spec-
trometry-based method to identify novel SPPL3 substrates in
a more systematic fashion. Our first experimental approach
followed the rational that ectopic SPPL3 overexpression
should lead to a quantitative increase of SPPL3 substrate
ectodomains in the secretome compared with control cells
with endogenous SPPL3 expression. Using the SPECS
method, we determined and quantitatively compared the gly-
coprotein secretome of HEK293 cells inducibly overexpress-
ing SPPL3 (Fig. 1). The same cell line without doxycycline
induction served as a control, ensuring that essentially iden-
tical cell populations were compared and ruling out the pos-
sibility that cell line- or clone-specific effects result in false
positive hits. Under these experimental conditions, we repro-
ducibly detected secretion of 428 proteins with a protein and
peptide false discovery rate of 1%, of which the majority
(48.5%) were annotated as secreted proteins and 29.4% and
18.6% as type I and type II transmembrane proteins, respec-
tively, suggesting that the latter had undergone proteolytic
cleavage prior to secretion (Fig. 1A and Table I). The volcano
plot depicted in Fig. 1B summarizes changes in protein se-
cretion from cells ectopically expressing SPPL3 compared
with control cells. Statistically significant changes (p value
cutoff: 0.05) are shown above the dashed line. A substantial
number of proteins were more abundantly secreted from cells
overexpressing SPPL3 (Fig. 1B, top right quadrant). Type II
membrane proteins were strongly enriched constituting the
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FIG. 1. Secretome analysis of HEK293 cells ectopically expressing active SPPL3. A, Pie chart of all glycoproteins which have been
identified in at least 4 out of 5 biological replicates of the HEK293 secretome subdivided according to their topology and the presence of a
transmembrane domain. B, Volcano plot: Plotted is the negative lg of the p value (y axis) of log2 LFQ values versus log2 LFQ ratio of SPPL3
overexpressing and control cells (x axis) of a given identified protein. The interspaced light gray line defines the significance level of p  0.05
(Student’s t test, multiple hypothesis testing was not applied). Almost exclusively type II membrane proteins clustered in the upper right
quadrant upon SPPL3 overexpression. The previously identified substrate MAN1B1 (9) is given in bold. C, Pie chart of all proteins that were
significantly increased in secretomes of HEK293 cells overexpressing SPPL3.
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1B, yellow circles and Fig. 1C). Furthermore, mapping of the
identified peptides against the protein topology of these hits
via QARIP analysis (23) revealed that, with the exception of
one single peptide, all detected peptides exclusively origi-
nated from extracellular/luminal protein moieties and did not
cover the N-terminal cytosolic or membrane-spanning re-
gions (supplemental Fig. S1). This suggests that these pro-
teins had undergone proteolytic processing prior to secretion
(supplemental Fig. S1). Table I lists all type II membrane
proteins that displayed a significantly increased or decreased
secretion upon SPPL3 overexpression, including, among oth-
ers, the previously identified SPPL3 substrate ER -manno-
sidase I (gene name: MAN1B1) (9). Secretion of a number of
proteins (Fig. 1B, red dots, top left quadrant and Table I)
including a few type II membrane proteins appeared to be
reduced following ectopic SPPL3 expression, suggesting that
SPPL3 overexpression may cause a reduced secretion of
these proteins. However, it was shown that in cells ectopically
expressing SPPL3, the extent of complex N-glycosylation is
diminished as overexpressed SPPL3 prematurely liberates
Golgi glycosyltransferases and thus impairs their intracellular
activity on nascent glycoproteins (9). In line with this, the
extent of terminal glycan sialylation may also be reduced,
resulting in a less efficient metabolic labeling of de novo
synthesized glycoproteins proteins with ManNAz and subse-
quent biotin labeling with bioorthogonal click chemistry. Thus,
it is more likely that the apparent reduction in secretion may
simply be because of less efficient metabolic labeling of gly-
coproteins in cells overexpressing SPPL3.
A number of the candidate SPPL3 substrates identified in
this first proteomic approach localize to the Golgi compart-
ment, for instance, the bifunctional heparin sulfate N-deacety-
lase/N-sulfotransferase 1 (NDST1) (24), 1,3-galactosyltrans-
ferase 6 (3GalT6) (25), the ER -mannosidase I (gene name:
MAN1B1) (26) and others. Individual other candidate substrates
were reported to localize to the ER (e.g. the O-mannose kinase
Sgk196 (27)) or even to the nuclear lamina (e.g. TOR1AIP1 (28)).
From a functional perspective (supplemental Table S7), the
TABLE I
Type II membrane proteins that are significantly altered ectopic expression of catalytically active SPPL3 in HEK293 cells. The table contains all
membrane proteins with type II orientation which are significantly (p value  0.05) increased or decreased upon SPPL3 overexpression. Those
type II proteins that were more abundantly secreted following SPPL3 overexpression are shown above the dotted line, those secreted less
below. Indicated are the names of the proteins, the gene name, number of unique peptides, the mean of the ratio between SPPL3
overexpression and control (con) of 5 biological replicates and the p value calculated with a two-sided, heteroscedastic t-test based on the log2
transformed LFQ values for the control and the SPPL3 overexpression condition. Previously published SPPL3 substrates are highlighted in bold,










Aspartyl/asparaginyl beta-hydroxylase ASPH 35 287.58 1.53E-04
Gamma-glutamyltransferase 7 GGT7 13 122.60 1.00E-06
Torsin-1A-interacting protein 2 TOR1AIP2 2 77.17 7.11E-05
Cytoskeleton-associated protein 4 CKAP4 17 21.11 6.05E-03
Exostosin-like 3 EXTL3 13 17.98 1.51E-02
Adipocyte plasma membrane-associated protein APMAP 6 17.93 8.08E-04
Glutaminyl-peptide cyclotransferase-like protein QPCTL 3 11.88 2.49E-03
Sodium/potassium-transporting ATPase subunit beta-1 ATP1B1 4 10.37 4.79E-05
Probable inactive protein kinase-like protein SgK196 SGK196 12 7.35 3.32E-05
Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase MAN1B1 14 6.99 9.64E-05
2-oxoglutarate and iron-dependent oxygenase domain-containing protein 3 OGFOD3 7 6.63 4.13E-03
Beta-1,4-galactosyltransferase 7 B4GALT7 3 5.96 8.16E-05
Heparan-sulfate 6-O-sulfotransferase 2 HS6ST2 15 5.05 1.28E-04
Beta-1,3-galactosyltransferase 6 B3GALT6 9 3.92 5.54E-04
Xylosyltransferase 2 XYLT2 15 3.27 9.39E-03
Alpha-mannosidase 2x MAN2A2 33 3.18 3.42E-03
Type 2 lactosamine alpha-2,3-sialyltransferase ST3GAL6 5 3.08 1.11E-02
Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 NDST1 21 3.05 1.48E-06
Protein ITFG3 ITFG3 4 2.78 3.34E-02
Endothelin-converting enzyme 1 ECE1 15 2.76 6.11E-04
Ectonucleoside triphosphate diphosphohydrolase 6 ENTPD6 10 2.71 1.49E-03
Fukutin-related protein FKRP 2 2.46 2.59E-02
Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase MGAT1 15 2.38 4.44E-02
Heparan-sulfate 6-O-sulfotransferase 1 HS6ST1 10 2.13 3.14E-02
Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 2 NDST2 14 1.90 3.52E-02
Heparan sulfate glucosamine 3-O-sulfotransferase 3B1 HS3ST3B1 9 0.58 4.27E-02
Cyclic AMP-dependent transcription factor ATF-6 alpha ATF6 3 0.36 3.06E-02
N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase B3GNT1 19 0.30 1.95E-02
Secretome Analyses Reveal Novel Substrates of SPPL3
1588 Molecular & Cellular Proteomics 14.6











type II membrane proteins identified are implicated in di-
verse cellular processes, but the majority of candidate sub-
strates has been linked to cellular Golgi glycan anabolism,
including N-glycosylation (e.g. -mannosidase 2x, gene
name: MAN2A2), glycosaminoglycan biosynthesis (e.g. exo-
stosin-like 3 (EXTL3)) and O-mannosylation (Sgk196).
In order to validate selected type II substrate candidates,
we next analyzed protein levels of selected candidate sub-
strates in TCA-precipitated conditioned supernatants and
whole-cell lysates of HEK293 cells. Transfection with candi-
date substrate-specific siRNA pools strongly reduced sig-
nals for secreted and cellular proteins demonstrating that
the antibodies used are specific. In control cells (Fig. 2 and
supplemental Fig. S2,  Dox) we observed constitutive se-
cretion of endogenous XylT2 (Fig. 2A), HS6ST2 (Fig. 2B),
HS6ST1 (Fig. 2C), 3GalT6 (Fig. 2D), Sgk196 (Fig. 2E), EXTL3
(Fig. 2F) and OGFOD3 (supplemental Fig. S2). A robust boost
in secretion of all candidate substrates was observed upon
ectopic expression of catalytically active SPPL3 (Fig. 2 and
supplemental Fig. S2,  Dox), fully confirming the SPECS
data (Fig. 1B and Table I). In addition, SPPL3 overexpression
reduced intracellular levels of some candidate substrates,
confirming that the increased secretion is facilitated by SPPL3
rather than by elevated intracellular protein levels. In contrast,
we detected no constitutive secretion of the candidate sub-
strates ASPH and TOR1AIP1, likely because secreted levels
were below the detection limit (supplemental Fig. S3). This
likewise explains the substantial boost of their secretion in
cells overexpressing SPPL3 (supplemental Fig. S3,  Dox),



























































































































































































































FIG. 2. Immunoblot validation of novel SPPL3 candidate substrates identified in HEK293 cells overexpressing catalytically active
SPPL3. Levels of secreted (s) and cellular XylT2 (A), HS6ST2 (B), HS6ST1 (C), 3GalT6 (D), Sgk196 (E), and EXTL3 (F) were analyzed by
immunoblotting in TCA-precipitated conditioned supernatants (sup) and whole-cell lysates, respectively, obtained from HEK293 cells. Where
indicated, cells were transiently transfected with nontargeting control siRNA pools (CTRL) or with siRNA pools specific for SPPL3 (20 nM).
siRNA pools targeting the individual substrates were transfected to control for antibody specificity. SPPL3 was ectopically expressed in a
HEK293 cell line stably transfected with SPPL3 under control of a doxycycline-sensitive repressor. To induce SPPL3 overexpression, media
were supplemented with doxycycline ( Dox) throughout the experiment, whereas control cells were left untreated ( Dox). In all panels
calnexin was used as a loading control. **, Sgk196 specific band of unknown nature.
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secretion observed in the proteomics screen (Fig. 1 and Table
I). Compared with all other candidate substrates the cytosolic
domain of TOR1AIP1 is relatively long (supplemental Fig. S1),
therefore the secreted cleavage product, detected with a
polyclonal antibody directed against TOR1AIP1’s luminal part,
is substantially smaller than full-length TOR1AIP1 (supple-
mental Fig. S3B). A mAb directed against the TOR1AIP1 N
terminus fails to detect this cleavage product confirming the
proteomics data (supplemental Fig. S1) and strengthening that
TOR1AIP1 is proteolytically cleaved from its N-terminal mem-
brane anchor by SPPL3 (supplemental Fig. S3B).
Because SPPL3 overexpression may lead to cleavage of
substrates that are not subject to proteolysis by SPPL3 under
physiological conditions, we investigated whether the basal
secretion of the candidate substrates may be likewise de-
pendent on endogenously expressed SPPL3. To this end, we
transiently knocked down SPPL3 expression in HEK293 cells
using specific siRNA pools (Fig. 2, supplemental Figs. S2 and
S3). Indeed, in supernatants of cells with reduced endoge-
nous SPPL3 expression, we observed a reduced secretion
for most of the candidate substrates tested (HS6ST2 (Fig.
2B), HS6ST1 (Fig. 2C), 3GalT6 (Fig. 2D), Sgk196 (Fig. 2E),
EXTL3 (Fig. 2F) and OGFOD3 (supplemental Fig. S2)). In
most cases, loss of SPPL3 did not completely abrogate
substrate secretion, indicating that, in addition to SPPL3,
other proteases may likewise execute substrate proteolysis.
In addition, some of the candidate substrates displayed an
intracellular accumulation of the full-length protein (HS6ST2
(Fig. 2B), HS6ST1 (Fig. 2C) and 3GalT6 (Fig. 2D)) com-
pared with cells transfected with control siRNA. Such an
accumulation could be because of an impaired proteolytic
turn-over as it was previously observed for other SPPL3
substrates (9).
Taken together, these experiments confirm our SPECS data
and demonstrate that SPPL3 facilitates shedding of these
newly identified substrates in an over-expression setting in
cell culture. Although probably other proteases or compensa-
tory effects also contribute to substrate shedding, endoge-
nous SPPL3 activity contributes to a certain extent to sub-
strate release under physiological conditions. Thus, our
biochemical validation corroborates that the proteins identi-
fied constitute genuine SPPL3 substrates.
Identification of Novel SPPL3 Substrates in Sppl3-deficient
Fibroblasts—Secretome analysis of cells ectopically express-
ing SPPL3 only identified one (ER -mannosidase I, MAN1B1)
of the previously described (9) SPPL3 substrates whereas
GnT-V (gene name: MGAT5), 4GalT1 (gene name:
B4GALT1), and 3GnT1 (gene name: B3GNT1, but recently
renamed to B4GAT1 (29, 30)) were not identified. However,
this is not surprising, as SPPL3 overexpression substantially
reduced intracellular levels of these endogenous glycosyl-
transferases, yet did not boost glycosyltransferase secretion,
which we consider an indication that cleaved glycosyltrans-
ferase ectodomains may be subject to intracellular degrada-
tion (9).
Hence, to uncover additional candidate SPPL3 substrates
that undergo proteolytic processing in a manner similar to
GnT-V, 4GalT1, and 3GnT1, we conducted a second
SPECS analysis that compared the secretomes of immortal-
ized murine embryonic fibroblasts (MEF) obtained from wild
type (Sppl3/) and Sppl3/ embryos (Fig. 3 and Table II).
We detected 330 proteins in at least four (of five) replicates
with a peptide and protein false discovery rate of 1%. The
majority of proteins identified are secreted proteins (59%),
whereas a smaller fraction of proteins are annotated to adopt
a type I and type II topology in the membrane, respectively (26
and 11%, Fig. 3A and supplemental Table S4). As illustrated
in a volcano plot (Fig. 3B), the quantitative comparison of the
two secretomes revealed substantial differences between the
secretome of Sppl3 knock out and the respective control
cells. Secretion of numerous proteins was found to be repro-
ducibly elevated (Fig. 3B, green dots) whereas secretion of
many others was reduced (Fig. 3B, red dots). Importantly, the
majority of secretome proteins with type II membrane protein
annotation (Fig. 3B, yellow dots) displayed reduced secretion
in Sppl3/ MEF (Fig. 3B) as expected for genuine SPPL3
substrates (9). Among these candidate Sppl3 substrates the
previously identified SPPL3 substrates GnT-V, 4GalT1 and
3GnT1 (reduced by 97%, 52%, and 74%, respectively) were
found (Fig. 3 and Table II). Similar to the results observed in
the overexpression approach, the list of type II membrane
proteins with altered secretion in Sppl3/ MEF includes
predominantly Golgi-localized type II membrane proteins im-
plicated in Golgi N- and also O-glycosylation but also other
cellular processes (Table II). Interestingly, NDST1, HS6ST1,
HS6ST2, MGAT1 and -mannosidase 2x (gene name:
Man2a2) can be found among the candidate substrates iden-
tified in both screening approaches (Tables I and II).
The reduced secretion of non-type II membrane proteins
from Sppl3/ MEF may not only be caused by the absence
of SPPL3 but can also result from cell line-specific properties
of the two distinct MEF cell lines (wild-type and Sppl3/)
compared. In light of this, hits unveiled in this setup require
careful validation to eventually be considered genuine SPPL3
substrates. Therefore, we analyzed selected candidate sub-
strates in Sppl3/ and Sppl3/ MEF as well as in the
HEK293 cell culture model (Fig. 4). As observed previously (9),
secretion of the Golgi glycosyltransferases GnT-V and
4GalT1 from Sppl3/ MEF was strongly reduced compared
with wild-type cells and was accompanied by an intracellular
accumulation of full-length glycosyltransferase levels (Fig.
4A). The same behavior was observed for the calcium-acti-
vated nucleotidase 1 (CANT1) implicated in glycosaminogly-
can biosynthesis (31), which was newly identified as candi-
date substrate in the mass spectrometry-based screen (Fig.
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4A). To further substantiate these findings, we analyzed en-
dogenous CANT1 in HEK293 cells treated with SPPL3-spe-
cific siRNA. Indeed, constitutive secretion of CANT1 was
blocked upon SPPL3 knockdown and at the same time the
protein accumulated intracellularly (Fig. 4B). Moreover, ec-
topic expression of catalytically active SPPL3 in HEK293 cells
led to a strong reduction of intracellular CANT1 levels,
whereas secreted CANT1 was slightly more abundant in con-
ditioned supernatants of these cells. The polypeptide
N-acetylgalactosaminyltransferase 10 (GalNAcT10), a Golgi
glycosyltransferase implicated in the initiation of mucin-type
O-glycosylation on serine/threonine residues, was analyzed
in a similar manner (Fig. 4B). Although we were not able to
detect MEF GalNAcT10 in Western blots of MEF cell lysates,
in HEK293 cells endogenous human GalNAcT10 was readily
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FIG. 3. Secretome analysis of Sppl3-deficient MEF. A, Pie chart of all glycoproteins which have been identified in at least four out of
five biological replicates of the MEF secretome subdivided according to their topology and the presence of a transmembrane domain. B,
Volcano plot: Plotted is the values of the negative lg of the p value of log2 intensity ratios (y axis) versus the log2 ratio of intensity values
of Sppl3 knockout MEF and wild type MEF (x axis) of a given identified protein. The interspaced light gray line defines the significance level
of p  0.05. Type II membrane proteins were almost exclusively reduced and thus clustered in the left half of the volcano. The previously
identified substrates are given in bold, those also identified in the SPPL3 overexpression secretome analysis in italics.
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lysates and displayed all expected features of a SPPL3
substrate (Fig. 4B).
To verify that altered secretion of type I transmembrane
proteins is rather because of cell line-specific adaptations of
Sppl3/ MEF versus control cells than because of SPPL3
mediated proteolysis, the type I membrane protein Integrin 5,
which displayed reduced secretion in the proteomic setup,
was analyzed in more detail. Confirming the SPECS analysis,
we observed a reduced secretion of Integrin 5 in conditioned
supernatants of Sppl3/ MEF compared with control cells
(Fig. 4C). However, contrasting with most genuine SPPL3
substrates, no accumulation of the intracellular Integrin 5
was apparent (Fig. 4C). Instead, Integrin 5 expression levels
were rather reduced in Sppl3/ cells compared with
Sppl3/ cells (Fig. 4C) accounting for the reduced Integrin
5 secretion in the Sppl3/ cells. Moreover, SPPL3 knock-
down neither impaired secretion of Integrin 5 nor resulted in
intracellular accumulation of the protein in the human cell
culture model (Fig. 4D). Similarly, overexpression of SPPL3
had no effect on Integrin 5 protein levels, hence, ruling out
that SPPL3 facilitates proteolytic cleavage of Integrin 5. Of
note, SPPL3 overexpression reduces the molecular weight of
the glycoprotein Integrin 5, which is well in line with previous
observations (9).
Taken together, secretome analysis of Sppl3-deficient MEF
revealed a number of type II membrane proteins that consti-
tute candidate SPPL3 substrates and we have thoroughly
validated this for CANT1 and GalNAcT10.
Cleavage Site Analysis of SPPL3 Substrates—In order to
determine general substrate requirements for SPPL3-medi-
ated intramembrane proteolysis, for instance primary se-
quence determinants within the substrate, it is crucial to in-
vestigate cleavage sites in multiple substrates. To date,
however, only the cleavage site of SPPL3 within GnT-V has
TABLE II
Type II membrane proteins which are significantly altered in secretomes of Sppl3/ MEF. Table contains all membrane proteins with type-II
orientation which are significantly altered upon Sppl3 knockout. Those type II proteins that were less abundantly secreted from Sppl3/ MEF
compared to control cells are shown above the dotted line, those secreted more below. Indicated are the names of the proteins, the gene name,
number of unique peptides, the mean of the ratio between Sppl3 knockout (KO) and control (wt) of five biological replicates and the p value
calculated with a heteroscedastic, two-sided student’s t-test based on the log2 transformed intensity ratios between the control and the SPPL3
overexpression condition. Previously published SPPL3 substrates are highlighted in bold, those identified also in the HEK293 SPPL3









Alpha-mannosidase 2 Man2a1 25 0.03 1.19E-11
Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Mgat5 13 0.06 6.60E-08
Agrin Agrn 30 0.04 7.97E-07
Soluble calcium-activated nucleotidase 1 Cant1 6 0.11 3.26E-05
Protein FAM198B Fam198b 14 0.21 8.12E-05
Carbohydrate sulfotransferase 14 Chst14 11 0.29 1.23E-04
N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase B3gnt1 5 0.26 1.36E-04
Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Mgat2 8 0.32 7.14E-04
Heparan-sulfate 6-O-sulfotransferase 1 Hs6st1 4 0.31 8.63E-04
Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase Gcnt1 6 0.45 1.21E-03
N-acetylated-alpha-linked acidic dipeptidase 2 Naalad2 12 0.27 1.26E-03
Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Mgat1 5 0.28 2.74E-03
Beta-galactoside alpha-2,6-sialyltransferase 1 St6gal1 4 0.34 5.02E-03
Carbohydrate sulfotransferase 12 Chst12 3 0.21 5.04E-03
UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 1 B3galnt1 2 0.35 6.25E-03
Alpha-mannosidase 2x Man2a2 6 0.51 9.39E-03
Beta-1,4-galactosyltransferase 5 B4galt5 4 0.33 1.02E-02
4F2 cell-surface antigen heavy chain Slc3a2 11 0.40 1.14E-02
Beta-1,4 N-acetylgalactosaminyltransferase 1 B4galnt1 6 0.44 1.16E-02
Mannosidase, alpha, class 1C Man1c1 6 0.53 1.27E-02
Beta-1,4-galactosyltransferase 1 B4galt1 4 0.52 1.36E-02
Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe Lfng 4 0.46 1.62E-02
Polypeptide N-acetylgalactosaminyltransferase 10 Galnt10 8 0.27 1.69E-02
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9 B3gnt9 4 0.34 2.13E-02
Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 Ndst1 5 0.63 2.37E-02
Integral membrane protein 2B Itm2b 2 0.70 2.43E-02
Exostosin-like 2 Extl2 4 0.61 3.17E-02
Golgi membrane protein 1 Golm1 5 0.34 3.42E-02
Heparan-sulfate 6-O-sulfotransferase 2 Hs6st2 9 0.68 4.28E-02
Aminopeptidase N Anpep 15 58.36 3.70E-10
Collectin-12 Colec12 10 4.44 2.98E-03
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been mapped in detail (9). Therefore, we searched peptide
data acquired in the course of the secretome analyses (Fig. 1
and 3) for semitryptic peptides spanning the C-terminal part of
the candidate substrates’ transmembrane domain and their
adjacent juxtamembrane domain. Among all identified semi-
tryptic peptides of type II membrane proteins we found a
number of peptides that originate within the C-terminal part of
the TMD of glycan-modifying enzymes and therefore are well
suited to infer the site of SPPL3-mediated endoproteolysis.
The suitability of these peptides to determine the cleavage
site of a protease is corroborated by the detection of the
semi-tryptic peptide N-LLHFTIQQR-C (Fig. 5), which origi-
nates from GnT-V/MGAT5 and fully confirms the cleavage site
of SPPL3 within GnT-V that was previously mapped by an
independent approach (9). Moreover, this semitryptic peptide
was identified both in samples from human and murine cells
FIG. 4. Immunoblot validation of novel candidate Sppl3 substrates identified in Sppl3-deficient MEF. Selected type II membrane protein
hits (A, B) and the type I membrane protein Integrin 5 (C, D) identified in the MEF secretome analysis (Fig. 3 and Table II) were validated by
immunoblotting using specific antibodies in Sppl3-deficient MEF (A, C) and in HEK293 cells (B, D). Secreted (s) and cellular amounts of the
respective protein hits were analyzed in TCA-precipitated conditioned supernatants (sup) and whole-cell lysates, respectively. Sppl3 knock-
down and overexpression in HEK293 cells (B, D) were achieved as detailed in Fig. 2. The previously identified Sppl3 substrates GnT-V (gene
name: MGAT5) and 4GalT1 (gene name: B4GALT1) were used as controls. In all panels calnexin was used as a loading control. *, nonspecific
band.
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indicating that the SPPL3 cleavage pattern is conserved
among species. Similar peptides originating from murine
4GalT1 and human ATP1B1 were detected (Fig. 5). Like for
GnT-V, ATP1B1 cleavage occurs within a membrane-embed-
ded Met_Leu-Leu motif and also the 4GalT1 cleavage site
shares a Leu residue in the P1 position (Fig. 5). In addition,
semi-tryptic peptides of the type II transmembrane proteins
B4GalT3 and A4GAT, which were not significantly altered in
either of the two screening approaches, were detected (Fig.
5). Moreover, tryptic peptides of the candidate substrates
GnT-I/MGAT1 and GnT-II/MGAT2 cover a region of the pro-
teins ectodomain close to the luminal TMD boundary, sug-
gesting that their original SPPL3 cleavage site locates N-ter-
minal to the detected membrane proximal tryptic cleavage
site, that is, to the predicted TMD.
Collectively, these data strongly corroborate the hypothesis
that Golgi type II membrane proteins are liberated from their
membrane anchors by intramembrane proteolysis and that
SPPL3 is crucially involved in this process.
DISCUSSION
Although SPPL3 was discovered more than 10 years ago
and is highly conserved in metazoans (1), initial studies on its
proteolytic and physiological function have been published
only very recently (8–10).
In the present study we provide the first systematic pro-
teomic identification of substrates for the intramembrane pro-
tease SPPL3, for which only few substrates have been de-
scribed before. We took advantage of SPPL3’s capability to
cleave full-length membrane proteins and mediate shedding
(8, 9) that renders SPPL3 glycoprotein substrates accessible
to proteomic analysis with the SPECS technology (16). The
majority of candidate substrates identified in proteomic anal-
yses of two distinct cell culture models localizes to the Golgi
compartment and is implicated in protein glycosylation (Ta-
bles I and II), confirming the crucial role of SPPL3 in regulation
of cellular glycosylation processes (9). Moreover, all previ-















FIG. 5. Cleavage site analysis of SPPL3 substrates. Selected semitryptic (red) and selected tryptic peptides (green) identified in the
secretome analyses are highlighted within the context of the respective full-length precursor and its TMD. An arrowhead indicates nontryptic
cleavage sites. TMDs are shown by dashed lines with Uniprot annotations given in green and TMHMM v2.0 predictions (http://www.cbs.dtu.dk/
services/TMHMM/) in blue. Nontryptic cleavage events are highlighted by a red arrowhead. MGAT5 and B4GALT1 were identified as SPPL3
substrates previously and were confirmed in this study (9) and ATP1B1, MGAT1, and MGAT2 were identified as novel candidate substrates.
B4GALT3 and A4GAT peptides were detected in proteomic datasets but no statistically significant differences in secretion following SPPL3
overexpression or Sppl3 knockout were observed. hs, human; mm, murine.
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firmed in at least one of the two secretome analyses (Figs. 1
and 3, Tables I and II), underpinning the reliability of the
experimental setups used.
Though we provide a much more extensive list of novel
substrates (Tables I and II) than aforementioned SPP and
SPPL2a/SPPL2b studies (14, 15), the outcome of proteome-
wide substrate screens is always restricted by the cellular
model system used, because the results only reflect the sub-
strate spectrum of a certain protease in the particular setup
and do not offer conclusions on substrate cleavage in other
cellular contexts or tissues. In addition, cell line-specific adap-
tions, as it is for example, the case for MEF cell lines derived
from litter-mate embryos, may result in a significant amount of
false positive hits. Finally, the SPECS method only allows for
enrichment of glycoproteins, that is, nonglycosylated candi-
date SPPL3 substrates could not be identified. Therefore, the
list of SPPL3 candidate substrates is certainly not yet com-
plete and future studies using other cellular or even in vivo
models will be required to complement our analyses. Because
of these limitations, it is moreover crucial to thoroughly vali-
date the identified candidate substrates using independent
detection technologies. In light of our previous observations
(9), validation of selected candidate substrates was per-
formed with a focus on proteins implicated in the cellular
glycosylation machinery. Western blot analyses confirmed
that secretion of XylT2, HS6ST1, HS6ST2, 3GalT6, Sgk196,
EXTL3, OGFOD3, ASPH, TOR1AIP1, CANT1, and GalNAcT10
is mediated in a SPPL3-dependent fashion (Figs. 2 and 4,
supplemental Figs. S2 and S3). However, comparison of sub-
strates identified in the SPPL3 overexpression setting (Fig. 2)
with those discovered in the Sppl3 knockout secretome anal-
ysis (Fig. 4) and previously identified substrates (9) revealed
that individual SPPL3 substrates are affected in a variety of
ways upon modulation of cellular SPPL3 activity in rather
variable manners. SPPL3 overexpression for instance sub-
stantially boosted secretion of ER -mannosidase 1 (9), XylT2,
EXTL3, and others (Fig. 2 and supplemental Figs. S2 and S3).
However, loss of cellular SPPL3 activity had differential ef-
fects on secretion of aforementioned substrates, for example,
a mild reduction of XylT2 (Fig. 2A) and a strong reduction of
EXTL3 (Fig. 2F). In contrast, secretion of GnT-V, 4GalT1,
CANT1 and GalNAcT10 (Fig. 4) were substantially reduced
following loss of SPPL3 activity. However, SPPL3 overexpres-
sion prominently reduced intracellular levels of these sub-
strates, whereas their secretion was not substantially boosted
pointing to an intracellular mechanism of ectodomain degra-
dation acting on SPPL3 cleavage products prior to secretion.
The latter is supported by the finding that secretion of the
substrate is strongly increased by simultaneous overexpres-
sion of both protease and substrate, as previously shown for
GnT-V (9).
These observations obviously raise questions regarding the
underlying mechanisms explaining these distinct effects. Ec-
topically expressed SPPL3 could in principle localize to ER/
Golgi subcompartments that normally do not harbor substan-
tial amounts of endogenous SPPL3 activity and thus
colocalize with substrates that are not efficiently cleaved un-
der physiological conditions. Nonetheless, these substrates
obviously harbor an intrinsic susceptibility to SPPL3-medi-
ated shedding and, consequently, SPPL3 activity must be
tightly regulated under physiological conditions. The proteo-
lytic activity of rhomboid serine intramembrane proteases,
which also are constitutively active toward full-length mem-
brane proteins in the Golgi is for instance tightly regulated by
subcellular compartmentalization of substrate and protease
(32). Hence, future work with a particular focus on the intra-
compartment colocalization of endogenous SPPL3 and its
substrates is required to understand how SPPL3 activity is
regulated.
Besides identifying numerous novel SPPL3 substrates, our
proteomic analyses provides a first glimpse on SPPL3 phys-
iological function that will be of crucial importance for future
research. Previous work delineated the impact of SPPL3-
mediated cleavage of glycosyltransferases on the nature and
extent of cellular N-glycosylation (9). In line with these find-
ings, we here report additional SPPL3 candidate substrates
implicated in N-glycosylation. However, our list of novel sub-
strates now suggests that SPPL3 may similarly modulate
other Golgi glycosylation pathways. We for instance identified
GalNAcT10 as SPPL3 substrate (Fig. 4B), which is a polypep-
tide-N-acetylgalactosaminyltransferase that catalyzes the
transfer of N-acetylgalactosamine residues to serine and thre-
onine residues, and in this way initiates mucin-type O-gly-
cosylation (33). SPPL3 may also impact O-mannosylation as
we identified the recently characterized Sgk196 (27) as
novel SPPL3 substrate. Likewise the SPPL3 substrate
3GnT1 (9) was recently implicated in this pathway (29, 30).
However, most prominent is the link of the newly identified
SPPL3 substrates to glycosaminoglycan biosynthesis. Sev-
eral substrates identified in the HEK293 (Fig. 1 and Table I)
and/or the MEF (Fig. 3 and Table II) secretome screen per-
formed are directly involved in cellular heparan sulfate biosyn-
thesis (Fig. 6 and supplemental Table S7). CANT1, which we
also extensively validated as SPPL3 substrate by immunoblot
analyses (Fig. 4A and 4B), has recently also been linked to
proteoglycan biosynthesis and mutations in CANT1 were
linked to chondrodysplasia (31). Hence, in the light of these
results, future functional studies are required to study whether
alterations in SPPL3 levels in vitro and most importantly in
vivo affect these various types of Golgi O-glycosylation in a
similar fashion like for N-glycosylation (9).
Shedding of Golgi glycosyltransferases and other glycan-
modifying enzymes is a well-documented phenomenon, yet
the physiological purpose, the destiny of the secreted ectodo-
mains and the proteases catalyzing the ectodomain release
have remained largely enigmatic (34). Cleavage and subse-
quent secretion of these enzymes has been discussed to
constitute a mechanism that allows for regulation of Golgi
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glycosylation. Nonetheless, it cannot be excluded that se-
creted glycosyltransferase ectodomains fulfill extracellular
functions or contribute to pathological processes. In that re-
gard, it is noteworthy that dysregulated secretion of xylosyl-
transferases has been linked with distinct pathological condi-
tions, such as for instance infertility in males (35) or skin
disorders (36). Results from the present study suggest that
SPPL3 is a major player in ectodomain release of these en-
zymes and thus regulates a variety of important physiological
processes.
Substrate requirements that determine SPPL3’s specificity
toward certain substrates have so far not been investigated in
more detail. Besides the type II topology of SPPL3 substrates,
SPPL3-substrate interaction may be critically influenced by
the primary sequence flanking the protease cleavage site.
However, so far, a precise SPPL3 cleavage site has only been
mapped within GnT-V (9). Hence, to learn more about the
cleavage mechanism of SPPL3, we analyzed semitryptic pep-
tides identified in both proteomic analyses. All semitryptic
peptides identified matched to the C-terminal region of the
predicted TMD or the luminal juxtamembrane domain of the
respective SPPL3 candidate substrate. Moreover, methio-
nine and tyrosine in the P1 position of the cleavage site were
the most abundant amino acids found (Fig. 5). Therefore, our
observations strongly corroborate that these substrates are
indeed liberated from their membrane anchors by intramem-
brane protease activity. In addition, secretome analysis, in
particular of human cells overexpressing SPPL3 revealed a
selective enrichment of candidate substrates that adopt a
type II topology within the membrane and localize to the ER
and/or Golgi network like SPPL3 (Fig. 1 and Table I). To-
gether, these findings strongly suggest that the substrates
identified in the secretome analysis are indeed genuine
SPPL3 substrates.
Although until now GxGD aspartyl intramembrane pro-
teases were believed to depend on helix-destabilizing resi-
dues in the substrates’ TMD and so far unidentified deter-
minants within the juxtamembrane domain for substrate
recognition and cleavage, rhomboid intramembrane pro-
teases seem to require a distinct consensus cleavage site in
or close to the luminal juxtamembrane domain of the sub-
strate (13, 37–39). Our findings point toward a putative SPPL3
cleavage consensus motif localized in a transmembrane do-
main part embedded adjacent to the luminal plasma mem-
brane boundary, which at least partially might influence
SPPL3 substrate selectivity. The fact that SPPL3 acts as a
sheddase for type II full-length substrates together with the
finding that SPPL3 cleavage may depend on primary se-
quence constraints supported by the repetitive detection of
similar cleavage site consensus motifs indicate that SPPL3
from a mechanistic perspective could rather be compared
with the rhomboid family than to the GxGD protease family.
However, the cleavage site analysis based on semitryptic
peptides has to be treated with caution, as detected cleavage
products could have undergone trimming by unrelated pro-
teolytic activities masking the original cleavage sites which is
a well-documented phenomenon for ST6Gal1 (40). In the
future, studies mutagenizing these SPPL3 cleavage sites
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FIG. 6. Schematic of the heparan sulfate biosynthesis. Heparan
sulfate biosynthesis on serine residues of proteoglycans is illustrated
according to (41). Enzymes involved in the individual steps are indi-
cated. The tri-saccharide precursor generated by GlucAT1 activity
can also give rise to chondroitin and dermatan sulfate glycosamino-
glycans (not depicted). Heparan sulfate polymerization is catalyzed by
successive addition of 1,4GlcA and 1,4GlcNAc by the EXT1/EXT2
heterodimer. SPPL3 substrates identified in the secretome analysis in
HEK293 cells overexpressing SPPL3 (red boxes), in Sppl3-deficient
MEF (green boxes), and in both (box filled with red-to-green gradient)
are highlighted.
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The present study provides the first systematic and com-
prehensive analysis of the SPPL3 degradome in cellular
model systems. Taken together, this not only complements
recent progress (9) on the physiological function of SPPL3 as
a regulator of Golgi-localized glycan-modifying enzymes, but
also raises additional novel fundamental physiological impli-
cations. In light of the newly identified SPPL3 substrates, a
much more general role in Golgi homeostasis can be attrib-
uted to SPPL3, because SPPL3’s function is not restricted to
the regulation of cellular N-glycosylation, but likewise extends
to O-glycosylation pathways in the Golgi apparatus and be-
yond. Finally, the study once more demonstrates the power of
the SPECS method in combination with mass spectrometry to
identify novel substrates of sheddases and paves the way for
further in-depth functional studies of SPPL3.
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Schröder, B., Haass, C., and Fluhrer, R. (2012) Foamy Virus Envelope
Protein Is a Substrate for Signal Peptide Peptidase-like 3 (SPPL3).
J. Biol. Chem. 287, 43401–43409
9. Voss, M., Künzel, U., Higel, F., Kuhn, P.-H., Colombo, A., Fukumori, A.,
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